{"entity":{"type":"insider","cik":"0001756211","url":"/insider/0001756211","json_url":"/insider/0001756211.json","name":"Neumann Mark","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":46,"n_filings":20,"first":"2019-10-17","last":"2024-08-20","span_basis":"filed_date"},"name_variants":[{"name":"Neumann Mark","source":"filing","n_filings":20,"first_seen":"2019-10-17","last_seen":"2024-08-20"}],"transactions":[{"id":3021483,"accession":"0000950170-24-099258","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-099258","line_url":"/filing/0000950170-24-099258#line-2","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18714.0,"shares_display":"18,714","price_per_share":75.08,"price_display":"75.08","price_state":"stated","total_value":1405047.12,"total_display":"1,405,047.12","total_whole":"1,405,047","shares_owned_after":29700.0,"shares_owned_after_display":"29,700","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-16","filed_date":"2024-08-20","scope":"insider"},{"id":2141095,"accession":"0000950170-24-029580","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-24-029580","line_url":"/filing/0000950170-24-029580","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7345.0,"shares_display":"7,345","price_per_share":65.61350442477877,"price_display":"65.61","price_state":"stated","total_value":481931.19,"total_display":"481,931.19","total_whole":"481,931","shares_owned_after":32742.0,"shares_owned_after_display":"32,742","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-11","filed_date":"2024-03-11","scope":"insider","n_lines":3},{"id":2141086,"accession":"0000950170-24-029580","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-029580","line_url":"/filing/0000950170-24-029580","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13132.0,"shares_display":"13,132","price_per_share":66.56857447456595,"price_display":"66.57","price_state":"stated","total_value":874178.52,"total_display":"874,178.52","total_whole":"874,179","shares_owned_after":34196.0,"shares_owned_after_display":"34,196","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-07","filed_date":"2024-03-11","scope":"insider","n_lines":2},{"id":2543190,"accession":"0000950170-24-021564","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-021564","line_url":"/filing/0000950170-24-021564","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7907.0,"shares_display":"7,907","price_per_share":70.12659668648034,"price_display":"70.13","price_state":"stated","total_value":554491.0,"total_display":"554,491.00","total_whole":"554,491","shares_owned_after":33348.0,"shares_owned_after_display":"33,348","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-26","filed_date":"2024-02-27","scope":"insider","n_lines":4},{"id":2512821,"accession":"0000950170-24-011394","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-011394","line_url":"/filing/0000950170-24-011394","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11860.0,"shares_display":"11,860","price_per_share":67.14734232715008,"price_display":"67.15","price_state":"stated","total_value":796367.48,"total_display":"796,367.48","total_whole":"796,367","shares_owned_after":29700.0,"shares_owned_after_display":"29,700","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-02","filed_date":"2024-02-05","scope":"insider","n_lines":2},{"id":8547634,"accession":"0001209191-23-054726","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-054726","line_url":"/filing/0001209191-23-054726","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":42393.0,"shares_display":"42,393","price_per_share":55.625964673413065,"price_display":"55.63","price_state":"stated","total_value":2358151.5204,"total_display":"2,358,151.52","total_whole":"2,358,152","shares_owned_after":45339.0,"shares_owned_after_display":"45,339","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-06","filed_date":"2023-11-08","scope":"insider","n_lines":2},{"id":8043766,"accession":"0001209191-23-045229","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-045229","line_url":"/filing/0001209191-23-045229#line-2","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55300.0,"shares_display":"55,300","price_per_share":58.79,"price_display":"58.79","price_state":"stated","total_value":3251087.0,"total_display":"3,251,087.00","total_whole":"3,251,087","shares_owned_after":45339.0,"shares_owned_after_display":"45,339","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-07","filed_date":"2023-08-09","scope":"insider"},{"id":7994938,"accession":"0001209191-23-021627","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-021627","line_url":"/filing/0001209191-23-021627","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15604.0,"shares_display":"15,604","price_per_share":54.305299282235325,"price_display":"54.31","price_state":"stated","total_value":847379.89,"total_display":"847,379.89","total_whole":"847,380","shares_owned_after":45339.0,"shares_owned_after_display":"45,339","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-28","filed_date":"2023-03-30","scope":"insider","n_lines":2},{"id":8544221,"accession":"0001209191-23-018286","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-23-018286","line_url":"/filing/0001209191-23-018286","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3758.0,"shares_display":"3,758","price_per_share":44.98181213411389,"price_display":"44.98","price_state":"stated","total_value":169041.65,"total_display":"169,041.65","total_whole":"169,042","shares_owned_after":61366.0,"shares_owned_after_display":"61,366","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-13","filed_date":"2023-03-13","scope":"insider","n_lines":2},{"id":8544213,"accession":"0001209191-23-018286","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-23-018286","line_url":"/filing/0001209191-23-018286","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8550.0,"shares_display":"8,550","price_per_share":43.34,"price_display":"43.34","price_state":"stated","total_value":370557.0,"total_display":"370,557.00","total_whole":"370,557","shares_owned_after":59157.0,"shares_owned_after_display":"59,157","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-10","filed_date":"2023-03-13","scope":"insider","n_lines":2},{"id":8214985,"accession":"0001209191-23-016024","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-016024","line_url":"/filing/0001209191-23-016024#line-1","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7241.0,"shares_display":"7,241","price_per_share":50.01,"price_display":"50.01","price_state":"stated","total_value":362122.41,"total_display":"362,122.41","total_whole":"362,122","shares_owned_after":49199.0,"shares_owned_after_display":"49,199","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-03","scope":"insider"},{"id":7868080,"accession":"0001209191-23-013442","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-013442","line_url":"/filing/0001209191-23-013442#line-2","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4046.0,"shares_display":"4,046","price_per_share":47.12,"price_display":"47.12","price_state":"stated","total_value":190647.52,"total_display":"190,647.52","total_whole":"190,648","shares_owned_after":56440.0,"shares_owned_after_display":"56,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-24","filed_date":"2023-02-27","scope":"insider"},{"id":8391677,"accession":"0001209191-23-012001","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-23-012001","line_url":"/filing/0001209191-23-012001","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3898.0,"shares_display":"3,898","price_per_share":47.0103412006157,"price_display":"47.01","price_state":"stated","total_value":183246.31,"total_display":"183,246.31","total_whole":"183,246","shares_owned_after":53338.0,"shares_owned_after_display":"53,338","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-21","filed_date":"2023-02-22","scope":"insider","n_lines":3},{"id":6369223,"accession":"0001209191-22-023901","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-023901","line_url":"/filing/0001209191-22-023901","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":86348.0,"shares_display":"86,348","price_per_share":64.36803678139621,"price_display":"64.37","price_state":"stated","total_value":5558051.24,"total_display":"5,558,051.24","total_whole":"5,558,051","shares_owned_after":60224.0,"shares_owned_after_display":"60,224","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-08","filed_date":"2022-04-08","scope":"insider","n_lines":3},{"id":6447780,"accession":"0001209191-22-013359","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-013359","line_url":"/filing/0001209191-22-013359","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7906.0,"shares_display":"7,906","price_per_share":52.214783708575766,"price_display":"52.21","price_state":"stated","total_value":412810.08,"total_display":"412,810.08","total_whole":"412,810","shares_owned_after":46710.0,"shares_owned_after_display":"46,710","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-24","filed_date":"2022-02-25","scope":"insider","n_lines":3},{"id":6508705,"accession":"0001209191-22-012394","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-22-012394","line_url":"/filing/0001209191-22-012394","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11139.0,"shares_display":"11,139","price_per_share":55.28567016787863,"price_display":"55.29","price_state":"stated","total_value":615827.08,"total_display":"615,827.08","total_whole":"615,827","shares_owned_after":49946.0,"shares_owned_after_display":"49,946","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-22","filed_date":"2022-02-23","scope":"insider","n_lines":2},{"id":6564497,"accession":"0001209191-22-002991","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-002991","line_url":"/filing/0001209191-22-002991","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20948.0,"shares_display":"20,948","price_per_share":40.779779453885816,"price_display":"40.78","price_state":"stated","total_value":854254.82,"total_display":"854,254.82","total_whole":"854,255","shares_owned_after":49591.0,"shares_owned_after_display":"49,591","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-10","filed_date":"2022-01-11","scope":"insider","n_lines":3},{"id":4840991,"accession":"0001209191-21-060907","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-060907","line_url":"/filing/0001209191-21-060907","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13448.0,"shares_display":"13,448","price_per_share":40.864906305770376,"price_display":"40.86","price_state":"stated","total_value":549551.26,"total_display":"549,551.26","total_whole":"549,551","shares_owned_after":52085.0,"shares_owned_after_display":"52,085","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-18","filed_date":"2021-10-19","scope":"insider","n_lines":4},{"id":4329916,"accession":"0001209191-21-012958","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-012958","line_url":"/filing/0001209191-21-012958","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5184.0,"shares_display":"5,184","price_per_share":39.218333333333334,"price_display":"39.22","price_state":"stated","total_value":203307.84,"total_display":"203,307.84","total_whole":"203,308","shares_owned_after":45939.0,"shares_owned_after_display":"45,939","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-19","filed_date":"2021-02-22","scope":"insider","n_lines":2},{"id":5144179,"accession":"0001209191-21-003319","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-003319","line_url":"/filing/0001209191-21-003319#line-2","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9684.0,"shares_display":"9,684","price_per_share":32.02,"price_display":"32.02","price_state":"stated","total_value":310081.68,"total_display":"310,081.68","total_whole":"310,082","shares_owned_after":39384.0,"shares_owned_after_display":"39,384","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-11","filed_date":"2021-01-12","scope":"insider"},{"id":2838608,"accession":"0001209191-20-055051","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-055051","line_url":"/filing/0001209191-20-055051#line-2","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6792.0,"shares_display":"6,792","price_per_share":26.8,"price_display":"26.80","price_state":"stated","total_value":182025.6,"total_display":"182,025.60","total_whole":"182,026","shares_owned_after":28120.0,"shares_owned_after_display":"28,120","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-16","filed_date":"2020-10-16","scope":"insider"},{"id":8240930,"accession":"0001209191-19-053435","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-053435","line_url":"/filing/0001209191-19-053435#line-2","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001756211","owner_name":"Neumann Mark","owner_display_name":"Neumann Mark","owner_url":"/insider/0001756211","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6774.0,"shares_display":"6,774","price_per_share":8.25,"price_display":"8.25","price_state":"stated","total_value":55885.5,"total_display":"55,885.50","total_whole":"55,886","shares_owned_after":6674.0,"shares_owned_after_display":"6,674","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-10-16","filed_date":"2019-10-17","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":46,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":46,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":46},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001567514","name":"Intra-Cellular Therapies, Inc.","url":"/issuer/0001567514","role":"Officer (EVP, Chief Commercial Officer)","n_filings":20,"first_seen":"2019-10-17","last_seen":"2024-08-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001756211","retrieved_at":"2026-08-24T15:30:04+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}